EUVIMED · CrossrefJournal
Journal of Clinical Oncology
ISSN 0732-183X · American Society of Clinical Oncology (ASCO)
Latest articles
Into the Unknown: Regulatory Perspective on Identifying Optimized Dosages of Oncology Radiopharmaceutical Therapies
Effect of a Multidisciplinary Intervention on Fatigue in Lymphoma Survivors With Persistent Fatigue: A Randomized Controlled Trial (the REFUEL trial)
Rethinking Regulatory Protections for Accelerated Approvals With Supplementary Indications
Alectinib as Neoadjuvant Treatment in Potentially Resectable Stage III Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer: ALNEO Phase II Trial (GOIRC-01-2020-ML42316)
Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration
NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002
Therapeutic Strategy Concerns for BRAF V600E–Mutated Differentiated Thyroid Cancer
Reach of State-Mandated Insurance Coverage for Fertility Preservation in Patients With Cancer
Reply to: Therapeutic Strategy Concerns for BRAF V600E–Mutated Differentiated Thyroid Cancer
Reply to: “Tislelizumab With Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Questions on Treatment Tolerance and Follow-Up Duration” and “NRF2 Pathway Status and Maintenance Immunotherapy Exposure in EC-CRT-002”
Confronting Fatigue in Cancer Survivorship by Moving Beyond Interventions Targeting a Single Cause
Timing of Alectinib in Resectable ALK-Positive Non–Small Cell Lung Cancer: Lessons From ALNEO
Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Breast Carcinoma: 5-Year Results of the Multicenter, Randomized, Phase III IRMA Trial
Tumor Site Heterogeneity in OrigAMI-4: Biological Implications and Open Questions for OrigAMI-5
Reply to: Tumor Site Heterogeneity in OrigAMI-4: Biological Implications and Open Questions for OrigAMI-5
Unanswered Question Regarding CNS Prophylaxis in CD5-Positive Diffuse Large B-Cell Lymphoma
Enhancing Workforce Research Methodology to Match Patients' Need in Contemporary Oncology Practice
Reply to: Unanswered Question Regarding CNS Prophylaxis in CD5-Positive Diffuse Large B-Cell Lymphoma
Brachytherapy Returns to the Brain: The ROADS Trial and a Second Look at Cavity Radiosurgery
Dasatinib Dose Optimization With Weekend Drug Holiday for Improved Tolerability in Chronic Myeloid Leukemia (DasaHIT): A German Chronic Myeloid Leukemia Alliance Randomized Trial
Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index
Eosinophils in Breast Cancer: One for All and All for One
Second Cancer Risk in Female Survivors of Hodgkin Lymphoma: A National Cohort Analysis Across Treatment Eras
Retraction: PIN1, Cholesterol Biosynthesis, and Clinical Outcomes in Urothelial Carcinoma (UC): A Propensity-Weighted Real-World Clinicogenomic Analysis
Patient-Level Evaluation of Optimal Margin Width for Lumpectomy in Ductal Carcinoma In Situ: An Analysis of Patients in the National Cancer Database Special Study
Headwinds in Breast Cancer Research: The Case for Pragmatic Radiotherapy De-escalation Studies
Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial
Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial
Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505)
To Be Loved
Volumes
2026 · 9,9552025 · 8,8002024 · 8,1722023 · 8,1202022 · 7,4742021 · 6,4682020 · 7,8602019 · 7,5262018 · 8,2022017 · 7,8552016 · 7,9002015 · 7,4922014 · 7,5792013 · 7,0662012 · 7,4562011 · 6,9222010 · 5,9392009 · 5,3762008 · 5,5462007 · 5,3152006 · 4,9992005 · 5,1232004 · 4,4202003 · 9192002 · 7872001 · 6302000 · 5781999 · 5321998 · 5681997 · 4811996 · 4431995 · 4331994 · 4111993 · 3691992 · 3091991 · 3281990 · 3051989 · 2901988 · 2741987 · 319
EUVIMED